Skip to main navigation Skip to search Skip to main content

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours

  • Kamal S. Saini
  • , Miriam Koopman
  • , Diogo Martins-Branco
  • , P. Bossi
  • , S. Braendegaard Winther
  • , M. Brahmi
  • , I. Braña
  • , E. Calvo
  • , L. Castelo-Branco
  • , I. Colombo
  • , E. de Azambuja
  • , D. De Ruysscher
  • , R. Dienstmann
  • , A. M. Dingemans
  • , M. Ekholm
  • , C. Gallois
  • , V. Golfinopoulos
  • , E. Grande
  • , S. Halabi
  • , E. Le Rhun
  • O. Le Saux, N. B. Leighl, S. Lonardi, S. Lorenzen, D. Lorusso, G. Minniti, G. Mountzios, J. Oldenburg, S. F. Oosting, P. Osterlund, J. L. Perez-Gracia, A. Pellat, S. Piperno-Neumann, R. Plummer, C. Porta, K. Punie, I. Ray-Coquard, J. Remon, C. H. Ruhlmann, P. Rutkowski, L. L. Siu, S. Stacchiotti, C. Suarez, K. Suijkerbuijk, J. Taieb, D. Trapani, A. Valachis, H. W.M. van Laarhoven, A. Vogel, A. Zer, G. Pentheroudakis, S. Delaloge, C. Twelves
  • Cambridge University Hospitals NHS Foundation Trust
  • University Medical Centre Utrecht
  • European Society for Medical Oncology
  • Humanitas University
  • IRCCS Istituto Clinico Humanitas - Rozzano (Milano)
  • Odense University Hospital
  • Centre Léon Bérard
  • Hospital Vall d'Hebron & ARADyAL research network
  • Vall d'Hebron Institute of Oncology
  • START Madrid-CIOCC
  • NOVA University Lisbon
  • Ente Ospedaliero Cantonale
  • Université libre de Bruxelles
  • MAASTricht Radiation Therapy and Oncology clinic (MAASTRO)
  • County Hospital Ryhov
  • Linköping University
  • Université Paris Cité
  • European Organisation for Research and Treatment of Cancer Data Center
  • University of Texas MD Anderson Cancer Center
  • Duke University
  • University Hospital Zürich
  • University of Zurich
  • Princess Margaret Hospital Cancer Centre
  • IRCCS Istituto Oncologico Veneto - Padova
  • Technical University of Munich
  • University of Rome La Sapienza
  • IRCCS Istituto Neurologico Mediterraneo Neuromed - Pozzilli (IS)
  • Henry Dunant Hospital
  • Akershus University Hospital
  • University Medical Centre Groningen
  • Tampere University
  • Karolinska University Hospital
  • Cima Universidad de Navarra and “Instituto de Investigación Sanitaria de Navarra (IdISNA)"
  • Centro de Investigación Biomédica en Red (CIBER)
  • Navarra Medical Research Institute
  • Hôpitaux Universitaires Paris
  • Institut Curie (Paris)
  • Newcastle University
  • University of Bari Aldo Moro
  • University Hospital Policlinico
  • Ziekenhuis aan de Stroom
  • Institut Gustave Roussy
  • Maria Sklodowska-Curie Institute of Oncology
  • IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
  • University of Milan
  • IRCCS Istituto Europeo di Oncologia - Milano
  • Örebro University
  • University of Amsterdam
  • Amsterdam UMC
  • Toronto General Hospital
  • Technion-Israel Institute of Technology
  • Leeds Teaching Hospitals NHS Trust

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)
7 Downloads (Pure)

Abstract

Enumeration of lines of therapy (LoT) is critical across oncology for ensuring optimal patient care, establishing uniform eligibility for clinical trial enrolment, standardising use of real-world data and pooling data for research purposes. Building on an earlier proposal for assigning LoT in oncology, the European Society for Medical Oncology (ESMO) developed the ESMO adaptation of Lines of Systemic Therapy (EnLiST) framework applicable to solid tumours across the full range of common clinical settings. A Delphi process was adopted to reach a consensus between expert representatives of multiple stakeholder perspectives including medical oncologists, clinical trialists, regulators, academics, patient advocates, experts from the pharmaceutical industry and clinical research organisations, artificial intelligence professionals, funding body specialists and ethicists. EnLiST provides a set of standard definitions, the format of reporting LoT, the minimum required data to be recorded and guidelines for assigning LoT. In EnLiST, a LoT is separately assigned to systemic anticancer therapies in the early (eLoT), advanced (aLoT) and investigational (iLoT) settings; each expressed as two numerals separated by a decimal point (e.g. 1.0). A change in systemic anticancer therapy results in either a ‘New’ LoT, a ‘Modified’ LoT, or the ‘Same’ LoT. A New LoT results from clinical progression of disease or lack of adequate tumour response, and is recorded as the next sequential value to the left of the decimal point (e.g. following LoT 1.0, the New LoT will be LoT 2.0). If the change in treatment is for other reasons (e.g. intolerability), a Modified LoT is recorded and assigned the next sequential value to the right of the decimal point (e.g. following LoT 1.0, the Modified LoT will be LoT 1.1). EnLiST has been designed to serve the needs of a wide range of stakeholders while enhancing the quality of clinical care, clinical research and real-world data.

Original languageEnglish
Pages (from-to)608-623
Number of pages16
JournalAnnals of Oncology
Volume37
Issue number5
DOIs
Publication statusPublished - May 2026

Bibliographical note

Publisher Copyright:
© 2026 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.

Fingerprint

Dive into the research topics of 'ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours'. Together they form a unique fingerprint.

Cite this